David C Shackley
University of Salford
26 Papers
135 Citations
David C Shackley is an academic researcher from University of Salford. The author has contributed to research in topics: Medicine & Bladder cancer. The author has an hindex of 11, co-authored 17 publications.
Chat about Author
Papers
Variation in the prevalence of urinary catheters: a profile of National Health Service patients in England.
David C Shackley,Cameron Whytock,Gareth Parry,Laurence Clarke,Charles Vincent,Abigail Harrison,Amber John,Lloyd P. Provost,Maxine Power +8 more
TL;DR: Catheter prevalence in patients receiving NHS-funded care varies according to gender, age, setting and specialty, being most prevalent in males, younger people, hospitals and critical care.
54
Complications arising in the final year of life in men dying from advanced prostate cancer.
TL;DR: The commonest adverse events in the final year of life in men dying of advanced prostate cancer are those of LUTS, renal failure, anemia, and bone pain with almost half of men developing at least one of these.
53
Photodynamic therapy for superficial bladder cancer under local anaesthetic
David C Shackley,C.H. Briggs,A Gilhooley,Colin Whitehurst,Kieran O’Flynn,C D Betts,James Moore,Noel W. Clarke +7 more
TL;DR: To evaluate the use of local anaesthesia in 5‐aminolaevulinic acid (ALA) photodynamic therapy for superficial transitional cell carcinoma (TCC) of the bladder, and to provide further toxicity and tolerability data on this new method within the context of a phase 1 trial.
52
Light penetration in bladder tissue: implications for the intravesical photodynamic therapy of bladder tumours
TL;DR: The optical properties and depth of penetration of varying wavelengths of light in ex‐vivo human bladder tissue are assessed, using specimens of normal bladder wall, transitional cell carcinoma and bladder tissue after exposure to ionizing radiation.
51
The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK
TL;DR: To assess whether the increased use of prostate‐specific antigen (PSA) testing over the last 15 years has changed the way prostate cancer presents in an inner city UK population, where PSA screening rates might be expected to be lower than in epidemiological studies based in North America.
22